Cyclooxygenase-2 [COX-2] is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects

• Autorzy: Majka J. , Rembiasz K. , Migaczewski M. , Budzynski A. , Ptak-Belowska A. , Pabianczyk R. , Urbanczyk K. , Zub-Pokrowiecka A. , Matlok M. , Brzozowski T.
• Języki publikacji: EN

Abstrakty

EN

Mixed reflux of the gastroduodenal contents induces the esophageal mucosal damage and inflammation progressing chronic esophagitis and premalignant Barrett's esophagus (BE). The role of cyclooxygenase-2 (COX-2) and chronic inflammation in the progression of BE toward adenocarcinoma of the esophagus has not been extensively studied in experimental models of BE in animals and in human subjects. We evaluated the expression of COX-2 in rat model of BE and examined the usefulness of COX-2 expression in determining the risk of malignant transformation in patients with BE treated with argon plasma coagulation (APC) that allows for effective ablation of metaplastic mucosa (group A) without or with proton pump inhibitors (PPI). In addition, the group B of patients was subjected to laparoscopic Nissen's fundoplication and group K that served as control, received PPI treatment only. Expression of COX-2 was evaluated in fresh-frozen biopsy specimens obtained from the distal esophagus in all 60 patients before and 12 months after treatment. In experimental studies, eighty rats were surgically prepared with esophagogastroduodenal anastomosis (EGDA) resulting in chronic esophagitis. At 4 months, the esophageal damage in EGDA rats was evaluated by macroscopic and histological index score, the plasma IL-1ß and TNF- levels was determined by ELISA and the mucosal expression of COX-2 mRNA and COX-2 protein were assessed by RT-PCR and Western Blot, respectively. Chronic esophagitis was developed in all EGDA animals followed by the rise in the plasma TNF- and IL-1ß levels. Histology revealed extensive esophageal ulcerations with development of columnar epithelium, formation of mucus glands in squamous epithelium, intestinal metaplasia distant to anastomosis consisting of goblet cells, infiltration of inflammatory cells including plasma cells and lymphocytes. COX-2 mRNA was absent in the esophageal mucosa of sham-control animals but strongly upregulated in metaplastic Barrett's epithelium. In BE patients, the overexpression of COX-2 was documented in patients with dysplasia. After APC (group A) or Nissen's fundoplication (group B), the expression of COX-2 mRNA was markedly reduced and these effects were positively correlated with histopathological findings. Controls failed to show significant alterations in COX-2 expression. We conclude that 1) EGDA rats serve as the suitable model of the chronic esophagitis by the gastrointestinal refluxate resembling many features of those observed in human Barrett's esophagus, as confirmed by severe morphology changes, excessive release of proinflammatory cytokines TNF- and IL-1ß and overexpression of COX-2, and 2) the significant correlation of the degree of COX-2 overexpression with histopathological findings indicates the usefulness of this inducible biomarker as a valuable indicator of the risk of malignant transformation in patients with BE.

Słowa kluczowe

EN

cyclooxygenase-2; chronic inflammation; adenocarcinoma; pathophysiology; Barrett's oesophagus; experimental animal; man; oesophageal gastroduodenal anastomosis; interleukin 1beta; tumour necrosis factor-alpha; laparoscopic Nissen fundoplication; gastroesophageal reflux disease

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 2010
• Tom: 61
• Numer: 4
• Opis fizyczny: p.409-418,fig.,ref.

Twórcy

autor

Majka J.

• Jagiellonian University Medical College, 16 Grzegorzecka Street, 31-531 Krakow, Poland

autor

Rembiasz K.

autor

Migaczewski M.

autor

Budzynski A.

autor

Ptak-Belowska A.

autor

Pabianczyk R.

autor

Urbanczyk K.

autor

Zub-Pokrowiecka A.

autor

Matlok M.

autor

Brzozowski T.

Bibliografia

• Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 1987; 87: 301-312.
• Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976; 295: 476-480.
• Haggitt RC, Tryzelaar J, Ellis FH, Colher H. Adenocarcinoma compicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 1978; 70: 1-5.
• Lagergren J, Bergstrom R, Lingren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl Med 1999; 340: 825-831.
• Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26: 2-8.
• Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus and esophageal cancer: scientific review. JAMA 2002; 287: 1972-1981.
• Nishijima K, Miwa K, Miyashita T, et al. Impact of the biliary diversion procedure on carcinogenesis in Barrett's esophagus surgically induced by duodenoesophageal reflux in rats. Ann Surg 2004; 240: 57-67.
• Souza RF, Shewmake K, Terada LS, Spechler SJ. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002; 122: 299-307.
• Fein M, Ireland AP, Ritter MP, et al. Duodenogastric reflux potentiate the injurious effects of gastroesophageal reflux. J Gastrointest Surg 1997; 1: 27-33.
• Kaur BS, Triadafilopoulos G. Acid- and bile-induced PGE2 release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002; 283: G327-G334.
• Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenetic therapy. Semin Oncol 2004; 31: 2-11.
• Evett GE, Xie W, Chipman JG, Robertson DI, Simmons DL. Prostaglandin G/H synthase isoenzyme 2 expression in fibroblasts: regulation by dexamethason, mitogens and oncogenes. Arch Biochem Biophys 1993; 306: 169-177.
• Kuramochi H, Vallbohmer D, Uchida K, et al. Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. J Gastrointest Surg 2004; 8: 1007-1016.
• Tsujii M, DuBois RN. Alternations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
• Zimmermann KC, Sarbia M, Weber AA, Borchard RF, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.
• Morgan G. Deleterious effects of prostaglandin E2 in oesophageal carcinogenesis. Med Hypotheses 1997; 48: 177-181.
• Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116-1119.
• Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-1327.
• Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus-the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998; 93: 1033-1036.
• Caygill CP, Watson A, Reed PI, et al. Characteristics and regional variations of patients with Barrett's oesophagus in the UK. Eur J Gastroenterol Hepatol 2003; 15: 1217-1222.
• Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995; 109: 1541-1546.
• Majka J, Szlachcic A, Brzozowski T, et al. Funkcjonalne znaczenie wzajemnej interakcji aktywnosci cyklooksygenazy-2, nablonkowego czynnika wzrostu (EGF) i jego receptora w patogenezie przewleklego zapalenia przelyku w swietle badan klinicznych i doswiadczalnych. Gastroenterol Pol 2009; 16: 45-49.
• Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003; 13: 369-397.
• Konturek PC, Kania J, Burnat G, et al. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J Physiol Pharmacol 2005; 56(Suppl 5): 57-73.
• Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase-2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487.
• Migaczewski M, Budzynski A, Rembiasz K, et al. Quality of life of patients with gastroesophageal reflux disease after laparoscopic Nissen fundoplication. Videosurgery and Other Miniinvasive Techniques 2008; 3: 119-125.
• Migaczewski M, Budzynski A, Rembiasz K. Argon plasma coagulation (APC) for treatment of Barrett's oesophagus. Videosurgery and Other Miniinvasive Techniques 2009; 4: 102-109.
• Pera M, Brito MJ, Poulsom R, et al. Duodenal-content reflux esophagitis induces the development of glandular metaplasia and adenosquamous carcinoma in rats. Carcinogenesis 2000; 21: 1587-1591.
• Brzozowski T, Konturek PC, Chlopicki S, et al. Therapeutic potential of 1-methylnicotinamide against acute gastric lesions induced by stress: role of endogenous prostacyclin and sensory nerves. J Pharmacol Exp Ther 2008; 326: 105-116.
• Konturek PC, Burnat G, Hahn EG. Inhibition of Barrett's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007; 58(Suppl 3): 141-148.
• Eksteen JA, Scott PA, Perry I, et al. Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNF- lpha. Eur J Cancer Prev 2001; 10: 163-164.
• Fitzgerald RC, Abdalla S, Onwuegbusi BA, et al. Inflammatory gradient in Barrett's oesophagus implications for disease complications. Gut 2002; 51: 316-322.
• Abdalla SI, Sandreson IR, Fitzgeralld RC. Effect of inflammation on cyclooxygenase (COX-2) expression in benign and malignant oesophageal cells. Carcinogenesis 2005; 26: 1627-1633.
• Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96: 990-996.
• Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-1423.
• Tsuji M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-3340.
• Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002; 122: 1800-1807.
• von Rahden BHA, Stein HJ, Puhringer F, et al. Coexpression cyclooxygenase (COX-1, COX-2) and vascular endothelial growth factors (VEGF-a, VEGF-c) in esophageal adenocarcinoma. Cancer Res 2005; 65: 5038-5044.
• Hla T, Ristimaki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann NY Acad Sci 1993; 696: 197-204.
• Chung HY, Kim HJ, Kim JW, Yu BP. The inflammation hypothesis of aging: molecular modulation by calorie restriction. Ann NY Acad Sci 2001; 928; 327-355.
• Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
• Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-245.
• Triadafilopoulos G. Proton pomp inhibitors for Barrett's oesophagus. Gut 2000; 46: 144-146.
• Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease. Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-669.
• Abdalla SI, Lao-Sirieix P, Novelli MR, et al. Gastrin induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 2004; 10: 4784-4792.
• Haigh CR, Attwood SE, Thompson DG, et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003; 124: 615-625.
• Miyazaki Y, Shinomura Y, Tsutsui S, et al. Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. Gastroenterology 1999; 116: 78-89.
• Sawaoka H, Tsuji S, Tsuji M, et al. Expression of the cyclooxygenase-2 gene in gastric epithelium. J Clin Gastroenterol 1997; 25(Suppl 1): S105-S110.
• Sawaoka H, Tsuji S, Tsuji M, et al. Involvement of cyclooxygenase-2 in proliferation and morphogenesis induced by transforming growth factor alpha in gastric epithelial cells. Prostaglandins Leukot Essent Fatty Acids 1999; 61: 315-322.
• Konturek PC, Kania J, Burnat G, Hahn EG. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. J Physiol Pharmacol. 2006; 57(Suppl 12): 15-24.
• Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929-2934.
• Cheong E, Igali L, Harvey I, et al. Cyclooxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study. Aliment Pharmacol Ther 2003; 17: 379-386.
• Lin BR, Hsieh HT, Lee JM, Lai JR, Chen CF, Yu LC. Luminal hydrochloric acid stimulates rapid transepithelial ion fluxes in rodent esophageal stratified squamous epithelium. J Physiol Pharmacol 2008: 59: 525-542.
• Burnat G, Majka J, Konturek PC. Bile acids are multifunctional modulators of the Barrett's carcinogenesis. J Physiol Pharmacol 2010; 61: 185-192.